exRNAdisease

Entry Detail

---



General Information

Database ID: exR0275564 RNA Name: hsa-miR-34c-5p RNA Type: miRNA Chromosome: chr11 Starnd: + Coordinate: Start Site(bp): 111513451 End Site(bp): 111513473 External Links: hsa-miR-34c-5p

Disease Information

Disease Name: Advanced Adenoma Disease Category: Cancers MeSH ID: D000236 Type: Neoplasms/Neoplasms, Glandular and Epithelial Alias: Adenoma//Adenomas//Adenoma, Follicular//Adenomas, Follicular//Follicular Adenoma//Follicular Adenomas//Adenoma, Trabecular//Adenomas, Trabecular//Trabecular Adenoma//Trabecular Adenomas//Adenoma, Monomorphic//Adenomas, Monomorphic//Monomorphic Adenoma//Monomorphic Adenomas//Adenoma, Papillary//Adenomas, Papillary//Papillary Adenoma//Papillary Adenomas//Adenoma, Basal Cell//Adenomas, Basal Cell//Basal Cell Adenoma//Basal Cell Adenomas//Adenoma, Microcystic//Adenomas, Microcystic//Microcystic Adenoma//Microcystic Adenomas

Expression Detail

GEO ID: GSE25609 Description: Plasma microRNA profiling by microarray elucidates several candidate biomarkers for colorectal cancer screening Experimental Design: Cancer vs Control Case Disease Type: Advanced Adenoma Case Disease SubType: NA Case Sample: Advanced Adenoma Post surgery Control Sample: Control Number of Case: 20 Number of Control: 20 Number of Samples: 40

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ZDHHC17 chr12 76763588 76853696 + PHF19 chr9 120855651 120894896 - CD151 chr11 832887 839831 + ATXN7L3 chr17 44191805 44200113 - TNRC6B chr22 40044817 40335808 + GATAD2B chr1 153789030 153923360 - SEC61A1 chr3 128051641 128071683 + NFAT5 chr16 69565094 69704666 + NPTX1 chr17 80466834 80477843 - TMEM109 chr11 60914158 60923443 + SUPT6H chr17 28662198 28702679 + ARPP19 chr15 52547045 52569883 - PXDC1 chr6 3722614 3752026 - TRIO chr5 14143342 14532128 + AGTRAP chr1 11736084 11754802 + NCOA1 chr2 24491914 24770702 + JRK chr8 142657460 142681968 - TOB2 chr22 41433494 41446801 - NFKBIA chr14 35401511 35404749 - ANGEL1 chr14 76786168 76826246 - MTMR9 chr8 11284816 11328146 + AMER1 chrX 64185117 64205708 - NECTIN1 chr11 119623408 119729200 - MRPL19 chr2 75646783 75690851 + IGSF3 chr1 116574399 116667755 - FOSL1 chr11 65892049 65900573 - TKFC chr11 61333210 61353295 + CRTC3 chr15 90529923 90645345 + FGFRL1 chr4 1009936 1026898 + ZIC5 chr13 99962964 99971909 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001723 chr7 91924202 91948826 + hsa_circ_0001495 chr5 68470703 68471364 + hsa_circ_0000943 chr19 47421744 47440665 + hsa_circ_0000038 chr1 28800065 28802803 + hsa_circ_0001865 chr9 86292641 86293514 - hsa_circ_0001146 chr20 34241449 34246936 - hsa_circ_0001164 chr20 45891031 45923523 - lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC018521.1 chr17 47945424 47981736 + AC116913.1 chr15 66488658 66492109 - HCG18 chr6 30286690 30327382 - KCNQ1OT1 chr11 2608328 2699994 - LINC00665 chr19 36313067 36331770 - NEAT1 chr11 65422774 65445540 + SNHG7 chr9 136721366 136728184 - TERC chr3 169764520 169765060 - XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE25609 Sample Source: Blood Source Fraction: Plasma Platform: GPL8179 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 826 Sample treatment protocol: Briefly, samples were centrifuged at 1,600×g for 10 min at 4 ºC to spin down blood cells, and plasma was transferred into new tubes, followed by further centrifugation at 16,000×g for 10 minutes at 4ºC to completely remove cellular components. RNA Extract protocol: NA RNA library preparation protocol: Biotinylated cDNA were prepared with the Illumina® TotalPrep™ RNA Amplification Kit (Ambion).

Reference

PMID: 23267864 Title: Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study Author: Gir¨¢ldez MD, Lozano JJ, Ram¨ªrez G, Hijona E, Bujanda L, Castells A, Gironella M Journal: Clin Gastroenterol Hepatol. 2013 Jun;11(6):681-8.e3. Description: We investigated whether plasma levels of miRNA can differentiate patients with CRC from healthy individuals. We also investigated whether plasma samples from patients with premalignant neoplastic lesions, such as advanced adenomas (AAs), also had a different expression pattern of miRNAs.